Effect of L-dopa on dementia-related rigidity

Area of Science:

• Neuroscience
• Pharmacology
• Geriatrics

Background:

• Rigidity is a common motor symptom in both Parkinson's disease and dementia.
• Levodopa (L-dopa) is a primary treatment for Parkinson's disease, effectively managing motor symptoms.
• The pharmacological basis of rigidity in dementia remains less understood compared to Parkinson's disease.

Purpose of the Study:

• To investigate the efficacy of Levodopa (L-dopa) combined with benserazide in treating rigidity associated with dementia.
• To explore the potential pharmacological differences between dementia-associated rigidity and parkinsonian rigidity.

Main Methods:

• A randomized, placebo-controlled, crossover study design was employed.
• Fourteen consecutive patients diagnosed with dementia and exhibiting rigidity were enrolled.
• Patients received L-dopa 100 mg plus benserazide 25 mg or placebo, three times daily, for 7-day periods, with treatment crossover.

Main Results:

• Administration of L-dopa resulted in a significant mean 60% increase in cerebrospinal fluid homovanillic acid (CSF-HVA).
• Despite the biochemical changes, no patients demonstrated any clinical response or improvement in rigidity.
• No significant difference in efficacy was observed between L-dopa/benserazide treatment and placebo.

Conclusions:

• Levodopa (L-dopa) combined with benserazide is ineffective in alleviating rigidity in patients with dementia.
• The findings indicate that rigidity in dementia patients is pharmacologically distinct from the rigidity observed in Parkinson's disease.
• This study highlights the need for alternative therapeutic strategies for motor symptoms in dementia.